InMed Pharmaceuticals (INM) Change in Accured Expenses (2019 - 2026)
InMed Pharmaceuticals (INM) reported Change in Accured Expenses of $113837.0 for Q1 2026, up 270.87% on a YoY basis from $30694.4 in Q1 2025, and up 295.1% quarter-over-quarter from -$58348.0 in Q4 2025.
InMed Pharmaceuticals (INM) Change in Accured Expenses (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals has reported Change in Accured Expenses for 8 years, with the latest figure at $113837.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 270.87% year-over-year to $113837.0; the trailing twelve-month figure through Mar 2026 stood at -$118906.0 (down 198.0% YoY), and the FY2025 full-year result was -$249728.0, down 651.5% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $113837.0, up from -$58348.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $470728.0 in Q2 2024, with the low at -$642392.0 in Q3 2024.
- Historically, Change in Accured Expenses has averaged -$137505.2 across 5 years, with a median of -$104340.0 in 2024.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 253.19% — and 2024, when it surged 312.82%.
- InMed Pharmaceuticals' Change in Accured Expenses stood at -$349611.0 in 2022, then jumped by 169.04% to $241378.0 in 2023, then jumped by 48.98% to $359614.0 in 2024, then slumped by 116.23% to -$58348.0 in 2025, then surged by 295.1% to $113837.0 in 2026.
- The last three Change in Accured Expenses figures came in at $113837.0 (Q1 2026), -$58348.0 (Q4 2025), and -$274066.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 10.02 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 23.00 Mn |
| 10 | InMed Pharmaceuticals | 6.04 Mn | 796,124.14 | - | 113,837.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 113,837.00 |
| Mar 31, 2026 | 113,837.00 |
| Dec 31, 2025 | -58,348.00 |
| Dec 31, 2025 | -58,348.00 |
| Sep 30, 2025 | -274,066.00 |
| Sep 30, 2025 | -274,066.00 |
| Jun 30, 2025 | 99,671.00 |
| Jun 30, 2025 | 99,671.00 |
| Mar 31, 2025 | -66,621.00 |
| Mar 31, 2025 | -66,621.00 |
| Dec 31, 2024 | 359,614.00 |
| Dec 31, 2024 | 359,614.00 |
| Sep 30, 2024 | -642,392.00 |
| Sep 30, 2024 | -642,392.00 |
| Jun 30, 2024 | 470,728.00 |
| Jun 30, 2024 | 470,728.00 |
| Mar 31, 2024 | -104,340.00 |
| Mar 31, 2024 | -104,340.00 |
| Dec 31, 2023 | 241,378.00 |
| Dec 31, 2023 | 241,378.00 |